Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

OTC Lipitor? Why Pfizer made the right decision for the wrong reason.

Ira Nash, MD
Meds
August 15, 2015
Share
Tweet
Share

There were several news stories recently that reported that Pfizer had abandoned its efforts to have its Lipitor brand of atorvastatin made available over the counter (OTC), without a prescription. I was never a big fan of OTC statins, but I was struck by the reason that Pfizer put out:

The study did not meet its primary objectives of demonstrating patient compliance with the direction to check their low-density lipoprotein cholesterol (LDL-C) level and, after checking their LDL-C level, take appropriate action based on their test results.

Left unstated (and unclear) in this is exactly what the appropriate action was supposed to be. I guess they were implying that patients were supposed to check how they responded to the drug and then figure out if they should keep taking it, change the dose or seek professional advice about next steps.

Here’s the irony with that. The current practice guidelines of the American College of Cardiology and American Heart Association for the management of high cholesterol no longer advise physicians to check how patients respond to statin therapy, or to adjust the dose up or down to achieve a “target” LDL-cholesterol level. Instead, they suggest that we assess a patient’s overall cardiovascular risk using an online calculator, which includes consideration of the patient’s age, blood pressure and other risk factors, and then prescribe moderate or high-dose statin (or no statin) based on the result. No more checking the on-treatment LDL-cholesterol.

So it seems that Pfizer determined that they should not go forward because patients are not capable of doing what doctors are not supposed to do. Makes no sense to me.

Nevertheless, this strikes me as the right decision for the wrong reason. Despite the low toxicity and high therapeutic value of statins, I don’t think they should be offered OTC. The analogy with other formerly prescription-only medications like H2 blockers or antihistamines is poor. Those drugs are useful for episodic use for symptomatic conditions, not continuous treatment of silent ones.

Statins may be more like vitamins; something that (if indicated) should be taken regularly. Given the importance of cholesterol management, I believe that if a patient needs the drug, it should be prescribed at a therapeutic dose (higher than what was going to be offered OTC). If the patient doesn’t need the drug, then why take it at all? I also think that the best way to make that determination is in consultation with a physician.

Ira Nash is a cardiologist who blogs at Auscultation.

Prev

What does a doctor look like?

August 15, 2015 Kevin 5
…
Next

Patients can spot the fake: They need the authentic

August 15, 2015 Kevin 2
…

Tagged as: Cardiology, Medications

Post navigation

< Previous Post
What does a doctor look like?
Next Post >
Patients can spot the fake: They need the authentic

ADVERTISEMENT

More by Ira Nash, MD

  • Let’s stop trying to change what doctors do

    Ira Nash, MD
  • Keeping up with the rapid developments in mobile health technology

    Ira Nash, MD
  • Not all doctors are physicians

    Ira Nash, MD

Related Posts

  • A medical student finds a reason to dance

    Nikita Mittal
  • What’s wrong with crisis pregnancy centers?

    Nickey Jafari, MD
  • Beware the hazards of over-the-counter (OTC) pain medications

    Abeer Arain, MD, MPH
  • The FDA was wrong about Aduhelm

    M. Bennet Broner, PhD
  • When records are wrong, patients are at risk

    Denise Reich
  • Why staying ahead of your pain with opioids is the wrong advice

    Myles Gart, MD

More in Meds

  • Tofacitinib: a lesson in heart-immune health

    Larry Kaskel, MD
  • The case for regulating, not banning, kratom

    Heidi Sykora, DNP, RN
  • How India-Pakistan tensions could break America’s generic drug pipeline

    Adwait Chafale
  • The unfair war on buprenorphine

    Brian Lynch, MD
  • Drug giants face suit over hidden cancer risks

    Martha Rosenberg
  • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

    Adwait Chafale
  • Most Popular

  • Past Week

    • When language barriers become a medical emergency

      Monzur Morshed, MD and Kaysan Morshed | Physician
    • A doctor’s letter from a federal prison

      L. Joseph Parker, MD | Physician
    • The dangerous racial bias in dermatology AI

      Alex Siauw | Tech
    • A surgeon’s view on RVUs and moral injury

      Rene Loyola, MD | Physician
    • Pancreatic cancer racial disparities

      Earl Stewart, Jr., MD | Conditions
    • A sibling’s guide to surviving medical school

      Chuka Onuh and Ogechukwu Onuh, MD | Education
  • Past 6 Months

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • How one physician redesigned her practice to find joy in primary care again [PODCAST]

      The Podcast by KevinMD | Podcast
    • I passed my medical boards at 63. And no, I was not having a midlife crisis.

      Rajeev Khanna, MD | Physician
    • When language barriers become a medical emergency

      Monzur Morshed, MD and Kaysan Morshed | Physician
    • The measure of a doctor, the misery of a patient

      Anonymous | Physician
    • A doctor’s struggle with burnout and boundaries

      Humeira Badsha, MD | Physician
  • Recent Posts

    • Pancreatic cancer racial disparities

      Earl Stewart, Jr., MD | Conditions
    • What AI can never replace in medicine

      Jessica Wu, MD | Physician
    • Why the MAHA plan is the wrong cure

      Emily Doucette, MPH and Wayne Altman, MD | Policy
    • Why burnout prevention starts with leadership

      Kim Downey, PT & Shari Morin-Degel, LPC | Conditions
    • Are SGLT2 inhibitors safe for type 1 diabetes?

      Zehra Haider, MD | Conditions
    • ChatGPT in medicine: risks, benefits, and safer documentation strategies [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • When language barriers become a medical emergency

      Monzur Morshed, MD and Kaysan Morshed | Physician
    • A doctor’s letter from a federal prison

      L. Joseph Parker, MD | Physician
    • The dangerous racial bias in dermatology AI

      Alex Siauw | Tech
    • A surgeon’s view on RVUs and moral injury

      Rene Loyola, MD | Physician
    • Pancreatic cancer racial disparities

      Earl Stewart, Jr., MD | Conditions
    • A sibling’s guide to surviving medical school

      Chuka Onuh and Ogechukwu Onuh, MD | Education
  • Past 6 Months

    • Rethinking the JUPITER trial and statin safety

      Larry Kaskel, MD | Conditions
    • How one physician redesigned her practice to find joy in primary care again [PODCAST]

      The Podcast by KevinMD | Podcast
    • I passed my medical boards at 63. And no, I was not having a midlife crisis.

      Rajeev Khanna, MD | Physician
    • When language barriers become a medical emergency

      Monzur Morshed, MD and Kaysan Morshed | Physician
    • The measure of a doctor, the misery of a patient

      Anonymous | Physician
    • A doctor’s struggle with burnout and boundaries

      Humeira Badsha, MD | Physician
  • Recent Posts

    • Pancreatic cancer racial disparities

      Earl Stewart, Jr., MD | Conditions
    • What AI can never replace in medicine

      Jessica Wu, MD | Physician
    • Why the MAHA plan is the wrong cure

      Emily Doucette, MPH and Wayne Altman, MD | Policy
    • Why burnout prevention starts with leadership

      Kim Downey, PT & Shari Morin-Degel, LPC | Conditions
    • Are SGLT2 inhibitors safe for type 1 diabetes?

      Zehra Haider, MD | Conditions
    • ChatGPT in medicine: risks, benefits, and safer documentation strategies [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...